Total Funding
54
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
Sio Gene Therapies is a clinical-stage biopharmaceutical company.
J. Fraser Wright: Chief Technology OfficerPast Role: Spark Therapeutics, Co Founder & Chief Technology Officer- Ilise Lombardo: Chief Medical OfficerPast Role: Kriya Therapeutics, Chief Medical Officer
About the Company
Sio Gene Therapies, formerly known as Axovant, is a clinical-stage company with a singular focus on pushing the boundaries of gene therapy to develop treatments for debilitating neurodegenerative diseases, including GM1 gangliosidosis, Tay-Sachs/Sandhoff disease, and Parkinson’s disease. Sio is leveraging its foundational scientific expertise
built on decades of research, extensive collaborations with leading gene therapy institutes, and a flexible vector platform to liberate patients with debilitating diseases through the transformational power of gene therapies.
